Casdatifan clinical trials
Also written AB521.
How each study uses casdatifan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the casdatifan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
10 studies that test it; most in 2025 (3)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 1
Arcus Biosciences, Inc. (7) · AstraZeneca (1) · Vanderbilt-Ingram Cancer Center (1) · Exelixis (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test casdatifan.
- Jan 2027A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCCPhase 1 · AstraZeneca
- May 2027Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic FunctionPhase 1 · Arcus Biosciences, Inc.
Studies
Open first, then newest update. How each study uses casdatifan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid TumorsRecruitingPhase 1Arcus Biosciences, Inc.NCT05536141Written as casdatifan
- Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell CarcinomaRecruitingPhase 3Arcus Biosciences, Inc.NCT07011719Written as Casdatifan
- Casdatifan for the Treatment of Refractory Metastatic Clear Cell Renal Cell CarcinomaRecruitingPhase 1Vanderbilt-Ingram Cancer CenterNCT07748988Written as casdatifan
- Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic FunctionRecruitingPhase 1Arcus Biosciences, Inc.NCT07751250Written as Casdatifan
- A Bioequivalence Study Between Two Casdatifan Tablet Strengths and Food Effect Study of Casdatifan in Healthy Adult ParticipantsCompletedPhase 1Arcus Biosciences, Inc.NCT07641881Written as Casdatifan
- A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCCActive, not recruitingPhase 1AstraZenecaNCT07000149Written as Casdatifan
- Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29)CompletedPhase 1Arcus Biosciences, Inc.NCT06919991Written as Casdatifan
- Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)TerminatedPhase 1ExelixisNCT06191796Written as AB521
- A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult VolunteersCompletedPhase 1Arcus Biosciences, Inc.NCT05999513Written as casdatifan
- Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healthy VolunteersCompletedPhase 1Arcus Biosciences, Inc.NCT05117554Written as casdatifan
Given beside what is tested · 3 — casdatifan is usual care or a partner of the new treatment
- A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)RecruitingPhase 1/2Bristol-Myers SquibbNCT07293351Written as Casdatifan
- Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell CancerRecruitingPhase 1/2PfizerNCT07227415Written as Casdatifan
- Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCCRecruitingPhase 2Dana-Farber Cancer InstituteNCT07397611Written as Casdatifan
Codes
What other systems call casdatifan · ClinicalTrials.gg INT016350
- UNII (FDA) DP73UWL6LECASDATIFANConfirmed FDA, Wikidata
- Wikidata Q140563593casdatifanConfirmed FDA, Wikidata
- NCI Thesaurus C192674CasdatifanOne source FDA
- DrugBank DB21701One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | DP73UWL6LE | CASDATIFAN | Confirmed FDA, Wikidata |
| Wikidata | Q140563593 | casdatifan | Confirmed FDA, Wikidata |
| NCI Thesaurus | C192674 | Casdatifan | One source FDA |
| DrugBank | DB21701 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.